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Background: Ablation of complex fractionated atrial electrograms (CFAE) is now
performed in patients with persistent atrial ﬁbrillation (AF). However, extensive ablation is
often necessary to eliminate all CFAE or to terminate AF. The purpose of this study was to
evaluate the eﬀects of antiarrhythmic drugs (AAD) on CFAE.
Methods and Results: Sixty patients, including 38 with longstanding persistent AF and 22
with persistent AF, underwent box isolation. After box isolation, CFAE maps were created
before and after infusion of a pure Naþ blocker, pilsicainide (1mg/kg), in 30 patients or a
pure IKr blocker, nifekalant (0.3mg/kg), in 30 patients. Nifekalant had a greater eﬀect on AF
termination than pilsicainide (33.3% versus 6.7%, P ¼ 0:01). Both AADs similarly reduced
CFAE. Ablation of CFAE localized by nifekalant and pilsicainide terminated AF in 26.7%
and 20% of the patients, respectively. After a single ablation procedure, patients in whom AF
was terminated by CFAE ablation had a lower recurrence rate than those in whom AF was not
terminated despite CFAE ablation (19.2% versus 35.3%, P ¼ 0:04).
Conclusions: Both pilsicainide and nifekalant reduce CFAE, and nifekalant has a greater
eﬀect on AF termination than pilsicainide. Ablation of only CFAE localized with AAD may
be suﬃcient for clinical eﬃcacy.
(J Arrhythmia 2011; 27: 314–323)
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Introduction
Pulmonary vein (PV) isolation is eﬀective for
treating paroxysmal atrial ﬁbrillation (AF),1,2) but is
not enough to cure persistent AF.3) To improve the
clinical outcome, extensive ablation, including abla-
tion of complex fractionated atrial electrograms
(CFAE) and multiple linear lesions, has been widely
adopted, particularly in patients with persistent
AF.4–9) CFAE are sometimes recorded over diﬀuse
areas and numerous ablation applications are often
necessary to eliminate all CFAE or to terminate AF.
It is also diﬃcult to distinguish culprit CFAE (e.g.
CFAE associated with perpetuating AF) from by-
stander CFAE. Although the most robust endpoint
may be termination of AF, this generally requires a
very long procedure.7) Furthermore, extensive abla-
tion is associated with procedural complications,
proarrhythmia,6) and stroke risk, and may compro-
mise atrial mechanical function.10) To minimize the
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extent of ablation required, we use antiarrhythmic
drugs before CFAE ablation in persistent AF.
However, it is unclear whether ablation of only
CFAE localized with a drug is suﬃcient for a
desirable outcome. Therefore, we conducted this
study to evaluate the eﬀects of a pure Naþ channel
blocker or a pure IKr channel blocker on CFAE and
to determine whether ablation of only CFAE




The study population consisted of 60 consecutive
patients (56 men and 4 women; mean age 56 10
years old) with persistent (n ¼ 22) and longstanding
persistent AF (n ¼ 38) who were referred for
catheter ablation guided by NavX system (NavX,
with CFE software, St. Jude Medical, Minnetonka,
MN, USA). Persistent AF was deﬁned as AF that
was sustained for more than seven days (mean, 6 2
months; range, 3 to 10 months) but which required
pharmacologic or electrical cardioversion. Long-
standing persistent AF was deﬁned as continuous AF
that had lasted for more than one year (mean, 59
45 months; range, 12 to 120 months). The mean LA
diameter was 45 5mm, the mean LA volume was
68 20ml, and the mean ejection fraction was
59 8%, as determined by echocardiography. The
mean LA appendage ﬂow was 48 14 cm/sec, as
determined by transesophageal echocardiography.
A mean of 2 1 anti-arrhythmic drugs had been
administered, but failed to maintain a normal sinus
rhythm. None of the patients had been treated with
amiodarone within the 6 months preceding the
procedure. No structural heart disease was present
in 26 patients. Hypertension was present in 31
patients and coronary artery disease was documented
in four. The patients were randomly assigned to
receive pilsicainide (n ¼ 30) or nifekalant (n ¼ 30).
There were no signiﬁcant diﬀerences in the patient
characteristics or substrate properties between the
two groups (Table 1). Patients who showed sponta-
neous termination of AF during or just after box
isolation or who had organized AF with little
CFAEs after box isolation were excluded from the
study.
Electrophysiological study
Written informed consent was obtained from all
patients. The patients received oral anticoagulants
for at least 2 months before ablation. Transesopha-
geal echocardiography was performed to exclude
any LA thrombi before ablation. Antiarrhythmic
drugs were discontinued ﬁve half-lives before
ablation. Two 5-Fr quadripolar electrode catheters
(St. Jude Medical, Minnetonka, MN, USA) were
placed in the high right atrium and coronary sinus.
Triple transseptal punctures were performed, and
three 8-Fr SL0 sheaths (St. Jude Medical,
Minnetonka, MN, USA) were advanced into the
LA. During the procedure, heparinization was
continued to maintain an activated clotting time of
350–450 seconds. The surface electrocardiograms
(ECG) and bipolar endocardial electrograms were
continuously monitored and stored on a computer-
based digital ampliﬁer/recorder system for oﬄine
analysis (LabSystem PRO, Bard Electrophysiol-
ogy, Lowell, MA, USA). The intracardiac electro-
grams were ﬁltered from 30 to 500Hz and measured
at a sweep rate of 200mm/s. Atrial pacing was
Table 1 Patient characteristics and outcome in pilsicainide and nifekalant groups
Clinical Factors Pilsicainide (n ¼ 30) Nifekalant (n ¼ 30) P Value
Sex, male/female 29/1 27/3 0.30
Age, y 55:9 8:5 55:8 11:8 0.72
Persistent AF/Longstanding persistent AF 11/19 11/19 1.0
AF duration, month 40:3 38:2 40:0 41:7 0.88
LA diameter, mm 44:5 4:0 45:9 6:3 0.16
LA volume, ml 66:4 20:3 69:8 18:4 0.18
LAA ﬂow, cm/sec 47:0 14:1 48:3 14:5 0.80
Ejection fraction, % 58:7 8:2 59:9 6:9 0.81
AF termination by drug, n (%) 2 (6.7%) 10 (33.3%) 0.01
AF termination by CFAE ablation, n (%) 6 (20%) 8 (26.7%) 0.20
Recurrence after 1st session, n (%) 9 (30%) 8 (26.7%) 0.25
Second session, n (%) 8 (26.7%) 6 (20%) 0.25
Recurrence after 2nd session, n (%) 1 (3.3%) 1 (3.3%) 0.51
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performed using a programmed stimulator (SEC-
3102, Nihon Kohden, Tokyo, Japan).
Two decapolar ring catheters (Lasso, Biosense-
Webster, Diamond Bar, CA, USA) were inserted into
the LA and used for the mapping of PVs. A deﬂect-
able, 7-Fr ablation catheter (Cool path duo, St. Jude
Medical, Minnetonka, MN, USA) was also inserted
into the LA for mapping and ablation. A 3D geometry
of the LA was created using the NavX system.
Box isolation
Ablation was performed during AF with an
irrigated-tip 4-mm ablation catheter. Radiofrequency
energy was delivered at a power of 30–40W. The
temperature was limited to 40 C. The luminal
esophageal temperature was monitored with a
catheter in the esophagus close to the tip of the
ablation catheter. During ablation at the posterior LA
close to the esophagus, cooling water was infused
into the esophagus through a tube just above the
catheter and ablation was performed at a maximum
power of 30W and a temperature of 40 C. If the
esophageal temperature was higher than 38 C, RF
applications were interrupted. Radiofrequency en-
ergy was delivered for 30 seconds at each point.
Continuous lesions at the anterior portions of the
ipsilateral superior and inferior PVs were initially
created under guidance of a Lasso catheter and the
NavX system. Ablation was started at the superior
wall and continued around the anterior and inferior
venous perimeter. At the posterior portions of the
PVs, ablation was sequentially targeted to antral
segments with the earliest activity until PV isolation
was achieved.
Ablation of the LA roof was then performed by
creating a contiguous line of ablation lesions to join
the superior PVs. Finally, ablation of the LA ﬂoor
was performed by creating a contiguous line of
ablation lesions that joined the inferior PVs to isolate
the posterior LA. The entrance block of a box lesion
during AF was conﬁrmed by the elimination of PV
and posterior LA potentials using a circular mapping
catheter.
Mapping of CFAE
After box isolation, CFAE mapping was per-
formed using a 4-mm-tip catheter during AF by
point-to-point contact mapping. Regarding the map-
ping sites for analysis, these were nearly equally
distributed in the LA, and the sampling sites were
collected from each of the subanatomical regions of
the LA except the box region, i.e., the anterior LA,
septal LA, anterior roof, inferior LA, lateral LA,
around the mitral annulus, and the LA appendage
region. In each region, at least 20 points were
determined. The points in each region were similar
in number and were nearly equally distributed. The
NavX mapping parameters were set to ‘‘CFE-mean,’’
which is an interval-analysis algorithm that produces
a color map that is representative of the CFAE
distribution. The CFAEs were characterized by
cycle-length values obtained from each site using a
recording duration of 6 seconds. This duration was
determined based on Lin’s11) report that the assess-
ment of fractionated electrograms required a record-
ing duration of 5 seconds at each site to obtain
a consistent fractionation. The parameters of the
automatic algorithm for CFAEs have been described
previously. According to the criteria proposed by
Nademanee et al.,5) CFAEs were deﬁned as fractio-
nated electrograms composed of two or more
deﬂections with a mean cycle length 120ms.
Non-CFAEs were deﬁned as having a mean cycle
length of >120ms.
Antiarrhythmic drugs
After complete CFAE mapping, pilsicainide
(1mg/kg) or nifekalant (0.3mg/kg) was adminis-
tered over 5 minutes. After drug administration, the
CFAE map was created again. The mean AF cycle
length at the coronary sinus, the maximal CFAE
(shortest cycle length), the mean degree of CFAE,
and the proportion of CFAEs in the LA (% of LA
with a mean cycle length <120ms) were compared
before and after drug administration.
Ablation of CFAE localized by antiarrhythmic drugs
After re-mapping, ablation of CFAE localized by
the drug was performed. The endpoint of CFAE
ablation was the elimination of all identiﬁable target
electrograms or termination of AF. If AF became
organized during ablation, mapping and ablation
were performed to terminate the organized tachy-
cardia. If the patient remained in AF despite the
elimination of all visible CFAE, electrical cardio-
version was performed to restore sinus rhythm.
During sinus rhythm, exit block of the box lesion
was conﬁrmed. Gaps along the ablation lines were
detected and closed using high voltage (10V) pace
mapping through the ablation catheter. With lack of
LA capture, the line was considered as complete
at this location. In case of LA capture, a gap was
suspected and RF energy was delivered simultane-
ously while pacing from the tip of the ablation
catheter. The endpoint of box isolation was deﬁned
as bidirectional conduction block, that is both lack
of potentials in box and lack of LA capture. AF
induction was not performed.
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Post-ablation care and follow-up
Intravenous heparin was administered to all pa-
tients for 24 hours after the procedure, followed by
warfarin for 3 months. After the ablation, all anti-
arrhythmic drugs were prescribed for 2 months to
prevent the early recurrence of AF. Surface ECG,
transthoracic echocardiography, and 24-hour Holter
recording were performed the day after the proce-
dure, and repeated at 1, 3, 6, and 12 months. All
patients were provided with a telemetry ECG record-
er (Omron HCG-801, Kyoto, Japan) for one month at
6 months after ablation to document symptomatic
episodes or to record an ECG once per week if
asymptomatic. AF recurrence was deﬁned as an
episode that lasted more than 1 minute and that was
conﬁrmed by ECGs 2 months after ablation (blanking
period). In the event of recurrent symptomatic or
asymptomatic arrhythmias, the patients were oﬀered
an additional ablation after a trial of drug therapy.
Statistical analysis
All of the statistical analyses were performed
using the SAS (Statistical Analysis System) Soft-
ware Package (Ver. 9.2, SAS Institute Inc., Cary,
NC). Categorical variables were compared between
groups by a 2 analysis with a Fisher’s exact test.
Continuous variables were compared between
groups by the Student’s t-test or Wilcoxon rank-
sum test. Data are presented as the mean SD.
Changes in the substrate properties before and after
drug administration were examined by the Wilcoxon
signed-rank test. Statistical signiﬁcance was set at a
P value less than 0.05.
Results
Effects of antiarrhythmic drugs on persistent AF
After box isolation, pilsicainide terminated AF in
2 patients (AF converted to sinus rhythm in 1 and
perimitral ﬂutter in 1) and nifekalant terminated AF
in 10 patients (AF converted to sinus rhythm in 7,
perimitral ﬂutter in 2, and typical ﬂutter in 1).
Nifekalant had a greater eﬀect on AF termination
than pilsicainide (P ¼ 0:01) (Table 1). In these
patients, re-mapping of CFAE and additional abla-
tion of CFAE could not be performed, and therefore,
these 12 patients were excluded from subsequent
analysis of the eﬀects of antiarrhythmic drugs on
CFAE characteristics.
Effects of antiarrhythmic drugs on CFAE
In 48 patients without AF termination, the LA
substrate characteristics were assessed before and
after the administration of antiarrhythmic drugs. As
shown in Table 2 and Figure 1, the LA substrate was
signiﬁcantly less fractionated in terms of the max-
imal CFAE (shortest cycle length), mean degree of
CFAE, and proportion of CFAE after both anti-
arrhythmic drugs. There were no signiﬁcant dif-
ferences in these substrate factors between pilsicai-
nide and nifekalant before and after administration.
The spatial distribution of CFAE in the LA also
diﬀered after antiarrhythmic drugs (Figure 1A).
Ablation of localized CFAE by antiarrhythmic drugs
In 28 patients who did not show AF termination
just after pilsicainide, ablation of localized CFAE
was performed, and terminated AF in 6 patients (AF
converted to sinus rhythm in 1, focal AT in 2,
perimitral ﬂutter in 2, and typical ﬂutter in 1).
Overall, 8 patients (26.7%) in the pilsicainide group
showed AF termination.
In 20 patients who did not show AF termination
just after nifekalant, ablation of localized CFAE
terminated AF in 8 patients (AF converted to sinus
rhythm in 4, focal AT in 3, and perimitral ﬂutter in 1)
Table 2 Substrate properties before and after antiarrhythmic drugs
Substrate Factors Before Drug After Drug P Value
Pilsicainide (n ¼ 28)
Mean AFCL, ms 147:5 10:6 196:3 14:5 <0:0001
Maximal CFAE (shortest CL), ms 46:6 5:8 53:1 8:4 <0:0001
Mean CFAE (mean CL), ms 70:6 6:8 82:5 9:1 <0:0001
Proportion of CFAE, % 56:2 8:9 27:9 12:9 <0:0001
Nifekalant (n ¼ 20)
Mean AFCL, ms 148:8 13:9 212:4 26:3 <0:0001
Maximal CFAE (shortest CL), ms 46:6 6:6 55:2 7:8 <0:0001
Mean CFAE (mean CL), ms 69:8 8:0 83:7 11:3 <0:0001
Proportion of CFAE, % 55:2 11:6 33:0 14:7 <0:0001
CL indicates cycle length. Twelve patients with AF termination by drug were excluded from analysis.
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(Figure 1). Overall, 18 patients (60%) in the nifeka-
lant group showed AF termination.
The mean number of RF applications to eliminate
CFAE was 16 12, and the total procedure time was
166 29 minutes.
In the pilsicainide group, after a single ablation
procedure, neither of 2 patients with AF termination
just after pilsicainide showed a recurrence of AF.
Three of 6 patients (50%) who showed AF termi-
nation by the ablation of localized CFAE showed a
recurrence of AF. Overall, 3 of 8 patients (37.5%)
with AF termination showed a recurrence of AF.
In contrast, 6 of 22 patients (27.3%) without AF
termination showed a recurrence of AF.
In the nifekalant group, after a single ablation
procedure, only 1 of 10 patients (10%) with AF
termination just after nifekalant showed a recurrence
of AF. Only 1 of 8 patients (12.5%) with AF
termination by ablation of localized CFAE showed a
recurrence of AF. Overall, 2 of 18 patients (11.1%)
with AF termination showed a recurrence of AF.
In contrast, 5 of 12 patients (41.7%) without AF
termination showed a recurrence of AF.
Difference in LA substrate between patients with
and without AF termination
Table 3 shows a comparison of the substrate
characteristics in patients with and without AF
termination. Patients with a longer AF duration,
lower LA appendage ﬂow, and shorter AF cycle
length were less likely to show AF termination. In
those patients, the LA substrate was signiﬁcantly
more fractionated in terms of the maximal CFAE,
mean CFAE, and proportion of CFAE compared
with patients with AF termination before and after
antiarrhythmic drug. After a single ablation proce-
E
Figure 1 Termination of AF by the ablation of localized CFAE with nifekalant.
A, Regional distribution of CFAE in the LA before and after nifekalant and the corresponding bipolar electrograms during AF. CFAE
mapping revealed multiple CFAE sites, including the LA septum, LA anterior wall, LA appendage base, and near the mitral annulus
region. Before nifekalant, both sites A and B showed CFAE, but after nifekalant only site B still showed CFAE. B, Intracardiac
electrograms during AF before nifekalant. A Lasso catheter was positioned in the LA appendage. The mean AF cycle length was 136ms.
C, After nifekalant, the mean AF cycle length was prolonged to 171ms. D, Ablation of CFAE at the anteroseptum successfully converted
to atrial tachycardia. E, Ablation of the focus at the anterior LA resulted in the restoration of sinus rhythm.
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dure, patients with AF termination by ablation of
localized CFAE had a signiﬁcantly lower recurrence
rate than those without AF termination despite
CFAE ablation (19.2% versus 35.3%, P ¼ 0:04).
Long-term follow-up
A second ablation procedure was performed in 14
patients (23.3%), including 8 patients in the pilsi-
cainide group and 6 patients in the nifekalant group,
who showed recurrence of AF. Patients with AF
termination had a lower incidence of second ablation
procedure than those without AF termination (11.5%
versus 36.7%, P ¼ 0:01).
At 17 7 months after the last ablation procedure,
55 patients (91.6%) were free of AF: 47 (78.3%)
without antiarrhythmic drugs and 8 (13.3%) with
antiarrhythmic drugs.
Discussion
Box isolation and CFAE ablation
Nademanee et al.5) described an electrogram-
guided approach by mapping and targeting areas of
CFAE as AF perpetuators, and reported that after
CFAE ablation, 87% of patients with persistent AF
and 78% of patients with longstanding persistent AF
were arrhythmia-free, including 11% of patients
taking antiarrhythmic drugs.9) We have provided an
alternative approach for complete isolation of the
posterior LA including all PVs, i.e., box isola-
tion.12,13) In our previous study, with box isolation
alone, 73% of the patients with persistent AF and
46% of the patients with longstanding persistent
AF were arrhythmia-free without antiarrhythmic
drugs.13) In these successful patients, CFAE ablation
was not necessary even if CFAE was present. In the
remaining patients who show recurrence of AF,
CFAE ablation may improve the success rate.
However, it is diﬃcult to identify patients who
require additional CFAE ablation. Therefore, we
used antiarrhythmic drugs before CFAE ablation to
reduce CFAE. A hybrid approach of box isolation
plus ablation of CFAE localized with antiarrhythmic
drugs is feasible and eﬀective for decreasing the
unnecessary ablation of bystander CFAE.
Effects of antiarrhythmic drugs on CFAE
Nademanee et al.9) used intravenous ibutilide to
highlight CFAE associated with perpetuating AF
after CFAE ablation, if the patient remained in AF
despite the elimination of all visible CFAE. They
demonstrated that the ablation of CFAE resulted
in the termination of AF in 95% of the patients,
however, 28% required concomitant ibutilide treat-
ment.7) In contrast, we used antiarrhythmic drugs
before CFAE ablation. Although antiarrhythmic
drugs might eliminate not only bystander CFAE
but also culprit CFAE, 11 of the 12 patients with AF
Table 3 Diﬀerence in patient characteristics and substrate properties between with and without AF termination
Parameters With AF termination(n ¼ 26)
Without AF termination
(n ¼ 34) P value
Age, y 55:7 11:4 56:1 9:3 0.90
Persistent AF/Longstanding persistent AF 12/14 10/24 1.0
AF duration, month 23:8 26:8 52:2 43:3 0.005
LA diameter, mm 44:9 5:7 45:3 5:0 0.61
LA volume, ml 63:3 16:3 71:8 21:5 0.11
LAA ﬂow, cm/sec 54:9 16:0 42:8 10:6 0.003
Mean AFCL before drug, ms 156:1 8:9 142:5 11:4 <0:0001
Mean AFCL after drug, ms 221:8 20:5 192:5 15:7 <0:0001
Maximal CFAE before drug, ms 50:0 5:7 44:0 5:1 <0:0001
Maximal CFAE after drug, ms 63:2 5:6 (n ¼ 14) 50:1 5:6 <0:0001
Mean CFAE before drug, ms 74:3 5:8 67:1 6:9 0.0003
Mean CFAE after drug, ms 92:6 4:4 (n ¼ 14) 78:7 8:2 <0:0001
Proportion of CFAE before drug, % 49:2 9:2 60:6 8:1 <0:0001
Proportion of CFAE after drug, % 20:5 8:1 (n ¼ 14) 38:7 7:1 <0:0001
Recurrence after 1st session 5 (19.2%) 12 (35.3%) 0.04
Second session 3 (11.5%) 11 (36.7%) 0.01
Recurrence after 2nd session 1 (3.8%) 1 (2.9%) 0.50
LAA indicates LA appendage; AFCL, AF cycle length.
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termination just after pilsicainide or nifekalant did
not show a recurrence of AF. Patients who showed
AF termination by ablation of localized CFAE had a
lower recurrence rate than those without AF termi-
nation by CFAE ablation. This suggests that most
CFAE that are eliminated by antiarrhythmic drugs
may be bystander CFAE, while antiarrhythmic drug-
resistant CFAE may be culprit for AF perpetuation.
In our previous study of CFAE ablation without
antiarrhythmic drugs, 30% of the patients with
persistent or permanent AF had a recurrence of
AF.14) In contrast, in the present study, 19% of the
patients who showed AF termination by CFAE
ablation with antiarrhythmic drugs had a recurrence
of AF. Thus, a recurrence rate of CFAE ablation
with antiarrhythmic drugs was not higher than that of
CFAE ablation without antiarrhythmic drugs. There-
fore, additional ablation of CFAE may not be
necessary when antiarrhythmic drugs terminate AF
after box isolation, and ablation of only CFAEs
localized with antiarrhythmic drugs may be suﬃ-
cient for clinical eﬃcacy.
Effects of Naþ channel blocker versus IKr channel
blocker on CFAE
Pilsicainide has pure Naþ channel blocking action
with slow recovery kinetics.15) Nifekalant is a
comparatively pure IKr channel blocker.
16) Both
pilsicainide and nifekalant similarly reduced CFAE
by prolonging the AF cycle length in non-driver
atrial tissue, probably due to the modiﬁcation of
refractoriness and conduction properties. These
drugs may block ﬁbrillatory conduction from focal
drivers and eliminate some CFAE.
We previously compared the eﬀects of pilsicai-
nide and nifekalant on the electrophysiological
properties of PV and LA in patients with AF.17)
Pilsicainide mainly prolonged the conduction time
within the PV rather than LA,18–20) whereas nifeka-
lant did not change the conduction time. Nifekalant
mainly prolonged the eﬀective refractory period of
LA rather than PV. Therefore, after box isolation,
nifekalant may have a greater eﬀect on atrial tissue
outside the box than pilsicainide. Naþ channels are
down-regulated by electrical remodeling in persis-
tent AF, whereas Kþ channels are not disturbed.21)
This may help to explain why nifekalant has a
greater eﬀect on AF termination than pilsicainide in
persistent AF.
Clinical implications
The endpoints of CFAE ablation are either the
termination of AF or the elimination of all CFAE.
However, this often requires a very long procedure
and extensive CFAE ablation is associated with
procedural complications. Lin et al.22) demonstrated
that PV isolation eliminated some CFAE, and
therefore complete PV isolation should be performed
before CFAE ablation to avoid unnecessary substrate
modiﬁcation. However, in persistent or longstanding
persistent AF, a long procedure is often needed to
achieve the endpoints of CFAE ablation even after
PV isolation. This study demonstrated that antiar-
rhythmic drugs localized CFAE and ablation of these
CFAE was suﬃcient for clinical eﬃcacy.
Limitations
First, the density of the mapping sites may not
have been high enough.
Second, the results of this study are in part based
on the eﬀect of an antiarrhythmic drug and the
ablation of CFAE after box isolation. Therefore, the
cumulative eﬀects may have led to the termination
of AF.
Conclusions
Both pilsicainide and nifekalant reduce CFAE,
and nifekalant had a greater eﬀect on AF termination
than pilsicainide. After a single ablation procedure,
patients with AF termination by ablation of localized
CFAE had a lower recurrence rate than those without
AF termination despite CFAE ablation. Ablation of
only CFAEs localized with antiarrhythmic drugs
may be suﬃcient for clinical eﬃcacy in the patients
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